India Pharma Outlook Team | Wednesday, 06 May 2026
Eli Lilly and Company reports a significant shift in Ulcerative Colitis (UC) treatment, with Omvoh sustaining disease clearance in patients for more than four years, setting a new standard in UC care.
As per the reports from the LUCENT-3 open-label extension study, 63.5 percent of Omvoh-treated patients achieving one year of disease clearance maintained it through four years. The findings, to be presented at the Digestive Disease Week (DDW), underscore a growing shift beyond symptom control towards sustaining disease clearance.
Adrienne Brown, Executive Vice President and President, Lilly Immunology, remarked, “Ulcerative colitis is a lifelong disease, and every person living with the condition deserves a treatment that can deliver strong and durable disease control, not just symptom relief.” She underscored the importance of disease clearance, citing data that demonstrated patients treated with Omvoh achieving and sustaining it through four years through consistent monthly dosing.
The data also shows that even under the most stringent measure – requiring endoscopic normalization alongside symptomatic and histologic remission, 61.3 percent of the patients who achieved it in a year maintained the results through four years.
Also Read: Profluent & Lilly Join Hands in 2.25 Billion USD Genetic Medicine Deal
Jean-Frédéric Colombel, M.D., Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at the Icahn School of Medicine at Mount Sinai, remarked on this achievement, “Until now, disease clearance has not been demonstrated for this length of time for any IL-23p19 therapy in ulcerative colitis. For a progressive disease like ulcerative colitis, that level of durable remission has the potential to change the long-term course of the disease for patients.”
The long-term safety profile of patients with moderate to severely active UC remained consistent with Eli Lilly and Company Omvoh’s established record of 12 percent reporting a serious adverse event, while 7 percent discontinued treatment due to an adverse event. During the three-year extension of LUCENT-3, one UC-related hospitalization and zero UC-related surgeries were reported.
Omvoh is currently approved in 47 countries for moderately to severely active UC and Crohn’s disease in adults.
.jpg)
.jpg)
